Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis - Université de Lorraine Access content directly
Journal Articles New England Journal of Medicine Year : 2019

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Dates and versions

hal-03144487 , version 1 (17-02-2021)

Identifiers

Cite

Bruce Sands, Laurent Peyrin-Biroulet, Edward Loftus, Silvio Danese, Jean-Frédéric Colombel, et al.. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381 (13), pp.1215-1226. ⟨10.1056/NEJMoa1905725⟩. ⟨hal-03144487⟩

Collections

UNIV-LORRAINE
16 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More